CION Ameerpet
A low-grade (Grade 2) glioma grows slowly — often over years, not weeks. With the right molecular tests and a clear plan, many people live well for a long time. At CION, your tumour is reviewed by a neuro-oncology team, not rushed.
Being told you have a glioma is frightening. But "low-grade" is an important word. A low-grade glioma is a WHO Grade 2 tumour that grows slowly — often over years rather than weeks. It begins in the brain's glial cells, the support cells that surround and protect nerve cells. The two main types are diffuse astrocytoma and oligodendroglioma, and they most often affect adults aged 20 to 45.
Slow-growing does not mean harmless. A low-grade glioma still infiltrates nearby brain tissue and can transform into a faster-growing tumour over time — which is why it needs lifelong specialist monitoring. The good news is that with modern glioma care, the conversation is usually about long-term control and quality of life, not a short timeline. This page explains how a Grade 2 glioma is classified, why molecular testing changes everything, and when to watch versus treat — written and reviewed by our brain tumour team.
Brain tumours are graded 1 to 4 by the World Health Organization (WHO) — not "staged" like other cancers. A low-grade glioma is Grade 2: the cells look only mildly abnormal under the microscope and grow slowly. Since the 2021 WHO classification, the diagnosis also depends on molecular markers such as the IDH mutation and the 1p/19q co-deletion, which the European Association of Neuro-Oncology (EANO) and NCCN guidelines use to guide treatment.
Grade 2 gliomas are not all the same. Their molecular subtype — defined by the IDH mutation and the 1p/19q co-deletion — shapes how they behave and how they are treated.
Arises from astrocytes, a type of glial cell. These tumours have indistinct edges and weave into normal brain tissue, which makes complete removal difficult. When the tumour carries an IDH mutation, it tends to grow more slowly and is linked to longer survival. Treatment is individualised — from watch-and-wait for small, fully-removed tumours to surgery, radiation, and chemotherapy when needed.
Arises from oligodendrocytes, the cells that insulate nerve fibres. By definition it carries both an IDH mutation and the 1p/19q co-deletion — a combination linked to a more favourable outlook and a better response to chemotherapy and radiation. Seizures are a common first sign. Many people live for many years, with treatment carefully sequenced to preserve quality of life.
Subtype is confirmed on tumour tissue. CION arranges the molecular tests that distinguish these two types as standard.
Because a low-grade glioma grows slowly, symptoms often build up gradually over months — and many tumours are first found after a single event. The most common first sign is a new seizure in a young or middle-aged adult. Other symptoms depend on where the tumour sits in the brain:
Red flags that always need an urgent brain MRI: a first-ever adult seizure; a new symptom that is persistent and progressive; sudden one-sided weakness, numbness, or loss of speech; or a sudden change in vision or hearing. Most headaches are not a tumour — but a new, persistent and worsening pattern deserves a check. Speak to a CION neuro-oncologist if any of these apply to you.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have just been diagnosed, want to understand your IDH and 1p/19q results, or are weighing watch-and-wait against treatment — CION's neuro-oncology team will walk this journey with you.
Getting the diagnosis right matters as much for a low-grade glioma as for any tumour — because the grade and molecular subtype decide everything that follows.
MRI is the gold standard for finding and characterising a glioma. A low-grade glioma typically shows up as an area that is bright on certain sequences and often shows little or no contrast enhancement — a feature that helps distinguish it from a high-grade tumour. Advanced sequences such as perfusion MRI and spectroscopy add information about how active the tumour is and how close it sits to areas controlling speech and movement.
Imaging can suggest a low-grade glioma, but only tumour tissue confirms the diagnosis, the exact subtype, and the molecular markers. Tissue is obtained either during surgical removal or, for deep or risky locations, through a stereotactic needle biopsy — both coordinated with accredited neurosurgical partners. At CION, every sample is sent for standard histology and molecular testing.
For a low-grade glioma, the molecular results matter as much as the grade. Two tests, run on the biopsy or surgical tissue, directly shape whether to watch, irradiate, give chemotherapy, or combine treatments.
IDH (isocitrate dehydrogenase) is an enzyme, and a mutation in the IDH gene is the single most powerful prognostic marker in glioma. Most low-grade gliomas are IDH-mutant — and IDH-mutated tumours grow more slowly and are associated with significantly longer survival than IDH wild-type tumours at the same grade. The 2021 WHO classification is built around this marker, which is why grade alone no longer tells the whole story.
The loss of part of chromosomes 1 and 19 — the 1p/19q co-deletion — defines an oligodendroglioma. Tumours with this co-deletion tend to respond better to chemotherapy and radiation and carry a more favourable outlook. Knowing this status at diagnosis is essential for an informed conversation about treatment. CION arranges IDH and 1p/19q testing as standard on every low-grade glioma sample, in line with NCCN and EANO guidance.
The European Association of Neuro-Oncology (EANO) and NCCN now classify low-grade gliomas primarily by their molecular profile, not appearance alone. An IDH-mutant, 1p/19q co-deleted tumour (oligodendroglioma) generally carries a more favourable outlook than an IDH wild-type tumour — even when both look the same on a scan. This is why a molecular workup should be part of the diagnosis of every glioma, and why a second opinion is worth seeking if it has not been arranged.
Gliomas are described by WHO grade, based on how aggressive the cells look under the microscope. A low-grade glioma is Grade 2 — the slow-growing end of the scale. The table below shows where it fits.
| Grade | Growth Rate | Typical Glioma Type | Usual Approach |
|---|---|---|---|
| Grade 1 | Very slow; often curable with surgery alone | Pilocytic astrocytoma | Surgery |
| Grade 2 (low-grade) | Slow; may progress over years | Diffuse astrocytoma, oligodendroglioma | Watch-and-wait, or surgery ± radiation/chemotherapy |
| Grade 3 | Moderately aggressive | Anaplastic astrocytoma/oligodendroglioma | Surgery + radiation + chemotherapy |
| Grade 4 | Highly aggressive | Glioblastoma (GBM) | Surgery + concurrent chemoradiation + chemotherapy |
Grade is only part of the picture. Molecular markers (IDH, 1p/19q) refine both the diagnosis and the prognosis. Learn more about how gliomas progress and transform over time.
One of the hardest things about a low-grade glioma is that the right next step is not always immediate treatment. For a small, symptom-free tumour with favourable markers, careful monitoring may be safer than rushing into radiation or chemotherapy. For others, early treatment gives the best long-term control. The decision is individual — and is best made by a tumour board, not a single clinician.
Active surveillance means delaying treatment while monitoring closely with scheduled MRI — usually every 3 to 6 months at first. It may be considered when the tumour is small, there are no troublesome symptoms, the molecular markers are favourable, and the tumour was fully or nearly fully removed at surgery. The aim is to avoid treatment side effects for as long as it is safe to do so. It is a planned strategy — not "doing nothing" — and treatment begins the moment scans or symptoms change.
Treatment is usually advised when the tumour is large, causing symptoms, growing on serial scans, or carries less favourable markers (such as IDH wild-type). The usual sequence is maximal safe surgical removal (coordinated with accredited neurosurgical partners), often followed by radiation therapy (IMRT/IGRT) and a course of chemotherapy — sequenced to balance tumour control against quality of life. CION delivers the radiation, systemic therapy, molecular testing, and seizure and steroid management directly.
Low-grade glioma care is a team effort. Surgery, radiation, and medical oncology work together from the start, and every plan is reviewed by our multidisciplinary tumour board.
When surgery is needed, the goal is to remove as much tumour as can be done safely while preserving brain function. The extent of safe removal is one of the strongest factors in long-term outcome. CION coordinates surgery with accredited neurosurgical partners — including neuronavigation-guided and awake-mapping approaches for tumours near speech or movement areas — while our team manages the diagnosis, molecular testing, and the radiation and systemic therapy around it.
For tumours that are larger, growing, or only partly removed, precise radiation can control the tumour for years. CION delivers IMRT and IGRT in-house — shaping the radiation beam to the tumour while sparing healthy brain. The timing of radiation is carefully judged, because for some favourable low-grade gliomas it is better to delay it until needed.
Chemotherapy is used for many low-grade gliomas, particularly oligodendrogliomas with the 1p/19q co-deletion and after radiation in higher-risk tumours. We describe treatment by drug class and mechanism rather than pushing a single brand — the right regimen depends on your molecular subtype and overall plan, decided by your medical oncologist.
Seizures are common with low-grade gliomas, so seizure and steroid management is a core part of care — delivered directly by CION alongside rehabilitation and symptom support. Looking for the full treatment pathway? See our brain tumour treatment in Hyderabad page.
A low-grade glioma is a long-term diagnosis, and the early decisions shape years of care. A second opinion is especially valuable in three situations:
CION offers a dedicated, free written second opinion reviewing your imaging, pathology, and existing plan. We make decisions for healing, not billing. Explore the wider brain cancer and tumour hub for related topics, including glioma and glioma progression.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable if molecular testing (IDH, 1p/19q) has not yet been arranged on your glioma.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A low-grade glioma is a slow-growing tumour that starts in the glial (support) cells of the brain. Under the World Health Organization (WHO) system it is graded Grade 2 — meaning the cells look only mildly abnormal under the microscope and grow slowly over years rather than weeks. The main types are diffuse astrocytoma and oligodendroglioma. They are most common in adults aged 20 to 45. Although slow-growing, low-grade gliomas are not benign — they infiltrate surrounding brain tissue and can, over time, transform into a higher grade. That is why they need long-term specialist monitoring even when treatment is not started straight away.
Yes — a Grade 2 glioma is classed as a malignant (cancerous) brain tumour, but it sits at the slow-growing, lower-risk end of the scale. It is very different from Grade 4 glioblastoma (GBM). Many people live for many years, and some for decades, with a Grade 2 glioma — especially when the tumour carries an IDH mutation and the 1p/19q co-deletion (seen in oligodendrogliomas), which are favourable markers. The word "cancer" is frightening, but with low-grade glioma the realistic conversation is about long-term control and quality of life, not a short prognosis. Outcomes depend heavily on tumour molecular type, age, and how much can be safely removed.
Treatment is individualised. For a small, symptom-free tumour found by chance, a careful watch-and-wait approach with regular MRI may be appropriate at first. When treatment is needed, the usual sequence is maximal safe surgical removal (coordinated with accredited neurosurgical partners), often followed — depending on age, remaining tumour, and molecular markers — by radiation therapy (IMRT/IGRT) and a course of chemotherapy. CION delivers the radiation, systemic therapy, molecular testing, and seizure and steroid management directly, and coordinates the neurosurgery with partner units. NCCN and EANO guidelines guide every decision, reviewed by our tumour board.
Watch-and-wait (active surveillance) means delaying treatment while monitoring the tumour closely with scheduled MRI scans — usually every 3 to 6 months at first, then less often if it stays stable. It is considered only for selected patients: a small tumour, no troublesome symptoms, favourable molecular markers, and tumour fully or nearly fully removed at surgery. The aim is to avoid the side effects of radiation and chemotherapy for as long as it is safe to do so. It is not "doing nothing" — it is a planned strategy that begins treatment the moment scans show growth or symptoms change. The decision should always be made with a neuro-oncology team.
Molecular markers now matter as much as the grade itself. The IDH mutation is the single most powerful prognostic marker — IDH-mutated low-grade gliomas grow more slowly and are linked to longer survival than IDH wild-type tumours. The 1p/19q co-deletion defines oligodendroglioma and predicts a better response to chemotherapy and radiation. These results, taken from the biopsy or surgical tissue, directly shape whether to watch, irradiate, give chemotherapy, or combine treatments. The 2021 WHO classification is built around these markers. CION arranges IDH and 1p/19q testing as standard on every low-grade glioma sample so the plan is built on the full molecular picture.
Yes — this is the most important reason for lifelong monitoring. Over months to years a Grade 2 glioma can transform into a faster-growing Grade 3 or Grade 4 tumour. The risk varies with molecular type: IDH wild-type tumours behave more aggressively, while IDH-mutated and 1p/19q co-deleted tumours transform more slowly. Warning signs include new or worsening seizures, a new neurological symptom, or an MRI showing faster growth or new contrast enhancement. Regular imaging is designed to catch transformation early, when treatment options are widest. You can read more about how gliomas progress and transform over time on our dedicated page.
The most common first sign is a seizure — often a first-ever seizure in a young or middle-aged adult — because slow-growing tumours irritate the surrounding brain. Other symptoms depend on location and may include persistent headaches that are worse in the morning, gradual one-sided weakness or numbness, speech or word-finding difficulty, vision changes, or subtle changes in memory, mood, or personality that family notice first. Because the tumour grows slowly, symptoms often build gradually over months. A first-ever adult seizure or any new, persistent and progressive neurological symptom should always prompt an urgent brain MRI. Speak to a CION neuro-oncologist if this applies to you.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.